Objective:To investigate the efficacy and toxicity of bortezomib in combination with dexamethasone and cyclophosphamide for the treatment of multiple myeloma.Method:Twenty-eight patients with multiple myeloma were treated with bortezomib (1.0~1.3 mg/m2) by intravenous bolus twice a week (day 1,4,8,11),cyclophosphamide (0.3 g/m2) by intravenous inject in the same day,dexamethasone 40 mg/d in the same day the next day. This regimen was repeated every 28 days as one cycle. The patients had received one to four courses. Before each course we had a check-up of bone marrow hemocytology,M protein and β2-microglobulin level. The adverse events were also observed. Result:①Clinical response was 100%,including complete response in 8(28%) patients,near complete response in 2 patients,partial complete response in 13 patients and minimal complete response in 5 patients. ② Bone marrow hemocytology,M protein and β2-microglobulin level before treatment were all significantly different from those after treatment (P0.05). ③The most common adverse events were gastrointestinal symptoms. Other adverse events included thrombocytopenia,herpes zoster and peripheral neuropathy. Conclusion:Bortezomib in combination with dexamethasone and cyclophosphamide is an effective therapy with a high response rate and tolerable toxicities for multiple myeloma patients.